Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT06970353

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

This phase II trial evaluates Tunlametinib (MEK inhibitor) ± PD-1 in NRAS-mutant advanced thyroid cancer. Key Objectives: Assess efficacy (ORR by RECIST v1.1)…

China40 participantsStarted 2025-05-27

Treatment: Tunlametinib, Tunlametinib+PD-1 mAb

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

All recent trials (1 shown)